Efficacy and safety of a recombinant hepatitis e vaccine in healthy adults: A large-scale, randomised, double-blind placebo-controlled, phase 3 trial

The Lancet

Volumn 376, Issue 9744, 2010, Pages 895-902

  Zhu, Feng Cai ^a   Zhang, Jun ^b   Zhang, Xue Feng ^a   Zhou, Cheng ^c   Wang, Zhong Ze ^d   Huang, Shou Jie ^b   Wang, Hua ^a   Yang, Chang Lin ^d   Jiang, Han Min ^d   Cai, Jia Ping ^d   Wang, Yi Jun ^d   Ai, Xing ^a   Hu, Yue Mei ^a   Tang, Quan ^a   Yao, Xin ^c   Yan, Qiang ^b   Xian, Yang Ling ^e   Wu, Ting ^b   Li, Yi Min ^e   Miao, Ji ^b   Ng, Mun Hon ^b   Shih, James Wai Kuo ^b   Xia, Ning Shao ^b   more..

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b XIAMEN UNIVERSITY   (China)

^c NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^d Dongtai Centre for Disease Control and Prevention   (China)

^e Xiamen Innovax Biotech ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

HECOLIN; HEPATITIS VACCINE; IMMUNOGLOBULIN G; RECOMBINANT VACCINE;

ADOLESCENT; ADULT; AGED; BLOOD; CHINA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHINA; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES; YOUNG ADULT;

EID: 77956618583     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61030-6     Document Type: Article

References (28)

1. AB Labrique, DL Thomas, SK Stoszek, KE Nelson Hepatitis E: an emerging infectious disease Epidemiol Rev 21 1999 162 179
2. RH Purcell, SU Emerson Prevention HC Thomas S Lemon AJ Zuckerman Viral hepatitis 3rd edn. 2005 Blackwell Publishing Malden, MA 635 645
3. HR Dalton, R Bendall, S Ijaz, M Banks Hepatitis E: an emerging infection in developed countries Lancet Infect Dis 8 2008 698 709
4. K Krawczynski, R Aggarwal, S Kamili Epidemiology, clinical and pathologic features, diagnosis, and experimental models HC Thomas S Lemon AJ Zuckerman Viral hepatitis 3rd edn. 2005 Blackwell Publishing Malden, MA 624 634
5. SU Emerson, RH Purcell Hepatitis E virus Rev Med Virol 13 2003 145 154
6. MS Khuroo, MR Teli, S Skidmore, MA Sofi, MI Khuroo Incidence and severity of viral hepatitis in pregnancy Am J Med 70 1981 252 255
7. MS Khuroo, S Kamili Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy J Viral Hepat 10 2003 61 69
8. S Kumar Acharya, P Kumar Sharma, R Singh Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death J Hepatol 46 2007 387 394
9. SS Hamid, M Atiq, F Shehzad Hepatitis E virus superinfection in patients with chronic liver disease Hepatology 36 2002 474 478
10. D FitzSimons, G Hendrickx, A Vorsters, P Van Damme Hepatitis A and E: update on prevention and epidemiology Vaccine 28 2010 583 588
11. EH Teshale, CM Howard, SP Grytdal Hepatitis E epidemic, Uganda Emerg Infect Dis 16 2010 126 129
12. S Emerson, D Anderson, A Arankalle Hepevirus CM Fauquet MA Mayo J Maniloff U Desselberger LA Ball Virus taxonomy: eighth report of the international committee on taxonomy of viruses 2004 Elsevier Academic Press London 853 857
13. RH Purcell, SU Emerson Hepatitis E: an emerging awareness of an old disease J Hepatol 48 2008 494 503
14. L Lu, C Li, CH Hagedorn Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis Rev Med Virol 16 2006 5 36
15. N Pavio, C Renou, G Di Liberto, A Boutrouille, M Eloit Hepatitis E: a curious zoonosis Front Biosci 13 2008 7172 7183
16. HC Worm, G Wirnsberger Hepatitis E vaccines: progress and prospects Drugs 64 2004 1517 1531
17. MP Shrestha, RM Scott, DM Joshi Safety and efficacy of a recombinant hepatitis E vaccine N Engl J Med 356 2007 895 903
18. J Zhang, CB Liu, RC Li Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine Vaccine 27 2009 1869 1874
19. SW Li, J Zhang, YM Li A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates Vaccine 23 2005 2893 2901
20. J Zhang, SX Ge, GY Huang Evaluation of antibody-based and nucleic acid-based assays for diagnosis of hepatitis E virus infection in a rhesus monkey model J Med Virol 71 2003 518 526
21. R Bendall, V Ellis, S Ijaz, P Thurairajah, HR Dalton Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response J Med Virol 80 2008 95 101
22. HR Dalton, S Hazeldine, M Banks Locally acquired hepatitis E in chronic liver disease Lancet 369 2007 1260
23. HR Dalton, RP Bendall, FE Keane Persistent carriage of hepatitis E virus in patients with HIV infection N Engl J Med 361 2009 1025 1027
24. B Said, S Ijaz, G Kafatos Hepatitis E outbreak on cruise ship Emerg Infect Dis 15 2009 1738 1744
25. HY Chen, Y Lu, T Howard Comparison of a new immunochromatographic test to enzyme-linked immunosorbent assay for rapid detection of immunoglobulin M antibodies to hepatitis E virus in human sera Clin Diagn Lab Immunol 12 2005 593 598
26. C Zhou, WJ Huang, X Yao Evaluation of the diagnostic kits for hepatitis E and establishment of a quantification method for detecting anti-HEV IgG Chin J Microbiol Immunol 29 2009 854 857
27. RC Li, SX Ge, YP Li Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China Emerg Infect Dis 12 2006 1682 1688
28. I Chan, N Bohidar Exact power and sample size for vaccine efficacy studies Commun Stat Theory Methods 27 1998 1305 1322